Skip to main content

Table 5 Weighted MAI sum-score by drug classes

From: Impact of training and structured medication review on medication appropriateness and patient-related outcomes in nursing homes: results from the interventional study InTherAKT

Primary endpoint: Descriptive results by ATC-class level 2

n = 83

MAI-Sum

M ± SD (n)

Mean difference

ATC-class level 2 a

t0

t1

t2

t2- t0

A02 – Drugs for acid related disorders

5.4 ± 3.8 (44)

3.4 ± 2.8 (45)

2.7 ± 2.5 (44)

−2.7 b

A06 – Laxatives

1.1 ± 2.1 (74)

0.4 ± 1.0 (79)

0.4 ± 0.9 (87)

−0.7

A07 – Antidiarrheals, intestinal antiinflammatory/antiinfective agents

1.5 ± 2.8 (15)

0.9 ± 1.8 (15)

0.5 ± 1.5 (11)

−1.0 b

A10 – Drugs used in diabetes

2.3 ± 3.3 (23)

2.6 ± 3.6 (27)

0.9 ± 1.9 (24)

−1.4 b

A11 – Vitamins

3.3 ± 2.5 (24)

2.4 ± 2.8 (31)

2.7 ± 3.2 (36)

−0.6

B01 – Antithrombotic agents

1.4 ± 2.4 (54)

1.1 ± 2.0 (56)

0.9 ± 2.0 (57)

−0.5

B03 – Antianemic preparations

2.2 ± 2.9 (13)

1.9 ± 2.6 (17)

2.2 ± 4.5 (19)

0.0

C01 – Cardiac therapy

3.1 ± 2.5 (18)

1.3 ± 1.9 (18)

0.5 ± 0.9 (17)

−2.5 b

C03 – Diuretics

1.7 ± 2.3 (51)

1.5 ± 2.2 (52)

1.4 ± 2.4 (51)

−0.3

C07 – Beta blocking agents

1.2 ± 1.8 (40)

1.5 ± 1.8 (37)

1.0 ± 1.5 (37)

−0.2

C08 – Calcium channel blockers

2.0 ± 2.7 (23)

1.5 ± 2.3 (23)

1.2 ± 1.7 (24)

−0.8

C09 – Agents acting on the renin-angiotensin system

0.9 ± 1.2 (40)

0.8 ± 1.2 (40)

0.5 ± 1.1 (40)

−0.4

C10 – Lipid modifying agents

1.1 ± 1.8 (25)

0.7 ± 1.4 (22)

0.5 ± 1.3 (22)

−0.6

D01 – Antifungals for dermatological use

5.7 ± 6.0 (19)

3.8 ± 4.4 (13)

2.4 ± 3.9 (10)

−3.3 b

D07 – Corticosteroids, dermatological preparations

4.6 ± 4.1 (14)

4.8 ± 2.9 (14)

3.9 ± 3.4 (12)

−0.7

G04 – Urologicals

2.0 ± 2.7 (12)

2.2 ± 1.9 (9)

2.0 ± 2.5 (8)

0.0

H03 – Thyroid therapy

2.8 ± 2.7 (22)

2.5 ± 2.5 (22)

2.4 ± 3.0 (22)

−0.4

M01 – Antiinflammatory and antirheumatic products

3.2 ± 3.3 (13)

1.0 ± 1.2 (11)

1.7 ± 2.9 (7)

−1.5b

N02 – Analgesics

1.5 ± 2.5 (94)

1.1 ± 1.7 (109)

0.8 ± 1.3 (99)

−0.7

N03 – Antiepileptics

1.1 ± 1.6 (20)

2.2 ± 2.2 (19)

2.4 ± 2.6 (21)

1.2 c

N04 – Anti-Parkinson drugs

3.4 ± 2.3 (21)

5.4 ± 4.8 (27)

3.6 ± 4.8 (27)

0.3

N05 – Psycholeptics

6.0 ± 5.7 (80)

4.4 ± 4.7 (89)

3.8 ± 4.7 (84)

−2.2 b

N06 – Psychoanaleptics

2.1 ± 2.2 (50)

2.8 ± 2.4 (43)

2.6 ± 2.5 (48)

0.5

R03 – Anti-asthmatics

7.8 ± 13.4 (26)

3.4 ± 3.6 (29)

2.7 ± 4.7 (26)

−5.1 b

S01 – Ophthalmologicals

4.9 ± 6.3 (27)

3.5 ± 2.9 (18)

3.0 ± 3.8 (22)

−1.9 b

  1. MAI-Sum Weighted MAI sum-score, M Mean, SD Standard deviation, (n) frequency of prescription
  2. a Only drug classes represented by > 10 prescriptions at baseline were considered
  3. b Strongest decreases of weighted MAI sum-score: mean difference ≤ − 1
  4. c Strongest increases of weighted MAI sum-score: mean difference ≥ + 1
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us